- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02846779
Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes (TARGIT-DM)
Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes (TARGIT-DM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In an era of rapidly growing healthcare costs, due to in large part to the increasing burden and complexity of chronic disease management, targeting outreach to patients who are most likely to benefit from them and tailoring interventions to individual patient needs, represent important opportunities to maximize healthcare value. The Targeted Adherence intervention to Reach Glycemic control with Insulin Therapy for patients with Diabetes (TARGIT-DM) trial is a pragmatic, intention-to-treat, randomized-controlled study that will evaluate the impact of three equivalently-priced strategies to improve insulin persistence and glycosylated hemoglobin [HbA1c] control among patients with diabetes on insulin.
The interventions in each of the three study arms will consist of educational mailings and telephonic pharmacist outreach. The pharmacists will assess and address potential barriers to insulin adherence and optimal glycemic control. The three study arms will employ differ both in regards to which patients are targeted and the intensity of the engagement strategy used. The low intensity intervention in arm 1 will be deployed to all subjects randomized to that arm. The moderate and high intensity interventions will be delivered to focused populations within arms 2 and 3, respectively, as defined by poor disease control and/or predicted risk of non-adherence. The interventions provided in the moderate and high intensity arms will also include feedback to the patient's provider, as needed, and potential enrollment in a text messaging program. Patients in these two arms who are not targeted will receive usual care.
The study population for this trial will consist of members enrolled in commercial insurance provided by Horizon Blue Cross Blue Shield of New Jersey. Insurance claims data will be used to apply the inclusion and exclusion criteria. Eligible patients will be randomized into one of three arms, stratified by baseline availability of HbA1c and a valid telephone number.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Newark, New Jersey, United States, 07105-2200
- Horizon Blue Cross Blue Shield of New Jersey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Commercially-insured individuals receiving medical and pharmacy health insurance benefits from Horizon Blue Cross Blue Shield of New Jersey
- At least 3 months of continuous enrollment prior to randomization
- At least 1 prescription for basal insulin, 6 months prior to randomization
- Type 2 diabetes diagnosis
Exclusion Criteria:
- Patients with Medicaid or Medicare as primary insurance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Low intensity
All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
|
Low intensity telepharmacy outreach
|
Experimental: Moderate intensity
Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program.
The pharmacist will also provide limited follow-up with the participant's provider.
Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
|
Moderate intensity telepharmacy outreach
|
Experimental: High intensity
Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up.
The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist.
Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
|
High intensity telepharmacy outreach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin Persistence
Time Frame: From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Percentage of participants who were non-persistent if they did not refill insulin before a set threshold of time over the entire follow-up period
|
From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glycated Hemoglobin Level (HbA1c)
Time Frame: From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
The percent change in HbA1c level between the latest baseline value to the latest follow up value, among those with at least 1 baseline HbA1c available.
|
From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Health Care Spending
Time Frame: From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Health care spending includes prescription medications, nondrug medical services, and the combination of these two factors over the entire follow-up period
|
From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Number of Physician Office Visits
Time Frame: From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Number of all-cause physician office visits over the entire follow-up period
|
From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Number of Emergency Room Visits
Time Frame: From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Number of all-cause emergency room visits over the entire follow-up period
|
From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Number of Hospitalizations
Time Frame: From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Number of All-cause hospitalizations over the entire follow-up period
|
From 1 month (30 days) after randomization through 12 months (365 days) after randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Lauffenburger JC, Lewey J, Jan S, Makanji S, Ferro CA, Krumme AA, Lee J, Ghazinouri R, Haff N, Choudhry NK. Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2019 Mar 1;2(3):e190657. doi: 10.1001/jamanetworkopen.2019.0657. Erratum In: JAMA Netw Open. 2019 Jul 3;2(7):e198448.
- Lewey J, Wei W, Lauffenburger JC, Makanji S, Chant A, DiGeronimo J, Nanchanatt G, Jan S, Choudhry NK. Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial. BMJ Open. 2017 Oct 30;7(10):e016551. doi: 10.1136/bmjopen-2017-016551.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016P000648
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on Low intensity
-
Queen's UniversityRecruiting
-
University of ArkansasLouisiana Tech UniversityRecruitingObesity, Childhood | Nutrition Aspect of CancerUnited States
-
University of California, BerkeleyUniversity of California, San FranciscoCompleted
-
Universidad Católica San Antonio de MurciaRecruiting
-
Virginia Polytechnic Institute and State UniversitySalem VA Medical Center; Washington DC VA Medical CenterNot yet recruitingChronic Pain | Opioid Use Disorder | Anxiety DisorderUnited States
-
Virginia Polytechnic Institute and State UniversityEnrolling by invitation
-
Kessler FoundationNational Cancer Institute (NCI); Kessler Institute for RehabilitationCompletedBreast CancerUnited States
-
Chongqing Medical UniversityRecruitingThe Therapeutic Effect of Low-intensity Focused Ultrasound on Painful Diabetic Peripheral NeuropathyPainful Diabetic NeuropathyChina
-
Medical University of South CarolinaDart Therapeutics. LLCRecruitingMajor Depressive Disorder | Treatment Resistant DepressionUnited States
-
Thomas AdamsUniversity of Texas at AustinNot yet recruiting